HLA-C and neoplasm: Increasing evidence suggests that CRT plays a role in the anti-cancer immune response, promoting a number of anti-tumor immune mechanisms such as improved antigen cross-presentation, increased type I interferon release, enhanced expression of major histocompatibility complex (MHC) class I on tumor cells, recruitment and maturation of dendritic cells, promotion of the infiltration of lymphocytes into the tumor and augmentation of cytotoxic T cell activation (4, 5).